학술논문
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
Document Type
Academic Journal
Author
Source
The New England Journal of Medicine. Sept 29, 2005, Vol. 353 Issue 13, p1332, 10 p.
Subject
Language
English
ISSN
0028-4793
Abstract
The Food and Drug Administration (FDA) required a study to measure the effectiveness of drotrecogin alfa (activated) (DrotAA) for adults who suffered from acute sepsis but with a low risk of death. Findings indicate that DrotAA should not be applied to patients with acute sepsis and low risk of death due to the lack of a beneficial treatment effect and with a high occurrence of severe bleeding complications.